Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + MK-4830 + lenvatinib
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of **pembrolizumab** (a monoclonal antibody targeting programmed death-1 [PD-1]), **MK-4830** (a monoclonal antibody targeting immunoglobulin-like transcript 4 [ILT4]), and **lenvatinib** (a small molecule multikinase inhibitor targeting VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT). The combination is being evaluated in clinical trials for advanced solid tumors and renal cell carcinoma. Pembrolizumab blocks PD-1 on T cells, releasing immune suppression and promoting anti-tumor immune activity. MK-4830, an investigational anti-ILT4 antibody, aims to further enhance the immune response by inhibiting myeloid cell-mediated suppression of anti-tumor immunity. Lenvatinib inhibits multiple tyrosine kinases involved in tumor growth, angiogenesis, and progression. This triple combination seeks to synergistically enhance anti-tumor activity via immune checkpoint inhibition, myeloid cell modulation, and targeted blockade of growth factor signaling pathways[1][2][3][4].
- Brand names
- KeytrudaLenvima
- Other names
- pembrolizumab + MK-4830 + lenvatinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR3 (Fibroblast growth factor receptor 3)CD274 (Programmed cell death protein 1 ligand 1)FGFR2 (Keratinocyte growth factor receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on pembrolizumab + MK-4830 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + MK-4830 + lenvatinib.